<DOC>
	<DOCNO>NCT00613132</DOCNO>
	<brief_summary>Primary objective To determine maximum tolerate dose &amp; dose limiting toxicity imatinib mesylate &amp; RAD001 combine w fixed dos hydroxyurea among pt w recurrent GBM &amp; enzyme-inducing anti-convulsants include pt anti-epileptic drug Secondary objective To assess safety &amp; tolerability imatinib mesylate combo w RAD001 &amp; hydroxyurea population To characterize single-dose &amp; repeated-dose pharmacokinetic profile imatinib mesylate &amp; RAD001 combo therapy pt population . To assess antiangiogenic effect , pre- post-treatment , imatinib mesylate , RAD001 &amp; hydroxyurea combo therapy , use DCE-MRI evaluate change extent vascular permeability , perfusion &amp; relative tumor blood volume ; explore assessment tumor cellularity &amp; tumor cell death change DWI-MRI quantitated apparent diffusion coefficient map .</brief_summary>
	<brief_title>Ph I Gleevec Combo w RAD001 + Hydroxyurea Pts w Recurrent MG</brief_title>
	<detailed_description>This open-label , single center , 1-arm ph I dose-escalation study continuous , daily dos imatinib mesylate &amp; RAD001 administer orally combination w fix dos hydroxyurea adult pt w recurrent relapse glioblastoma multiforme . Study format include classical `` 3+3 '' dose escalation design determine MTD &amp; DLT imatinib mesylate + RAD001 combine w hydroxyurea among GBM pt . Pts stratify base whether receive EIACD &amp; stratum independently dose escalate . Additionally , study characterize safety , tolerability , biologic activity , &amp; pharmacokinetic profile combo therapy .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Pts w confirm GBM , GS , AA , AO &amp; AOA present 1st , 2nd/3rd recurrence/relapse Pts without tumor biopsy &lt; 1 wk/surgical resection &lt; 2 wks prior start study drug For stratum nonEIAED pt , pt enzyme induce anticonvulsant &gt; 2 wks prior start study drug Pts nonincreasing dose steroid &gt; 7 day prior obtain baseline GdMRI brain Pts nonincreasing dose steroid &gt; 7 day prior start study drug Pts w previous implantation Gliadel may eligible discussion investigator &amp; sponsor Multifocal disease eligible Age &gt; 18 yr KPS &gt; 70 Hematology : ANC &gt; 1.5 x 10^9/L , Hgb &gt; 9 g/dL , Platelets &gt; 100 x 10^9/L Biochemistry : K≥ LLN/correctable w supplement , Total Ca≥ LLN/correctable w supplement , Mg≥ LLN/correctable w supplement , P≥ LLN/correctable w supplement , AST/SGOT &amp; ALT/SGPT &lt; 2.5 x ULN , Serum bilirubin &lt; 1.5 x ULN , Serum creatinine &lt; 1.5 x ULN/measured 24hr CrCl &lt; 0 mL/min/1.73m2 , &amp; Cholesterol≤ 00 mg/dL &amp; triglyceride≤2.5 ULN Life expectancy ≥12wks Written inform consent obtain prior screen procedure Pts w peripheral neuropathy ≥CTCAE gr2 Pts w unresolved diarrhea ≥CTCAE gr2 History impair cardiac function Obligate use cardiac pacemaker , Congenital long QT syndrome , History presence ventricular atrial tachyarrhythmias , Clinically significant rest bradycardia , Right bundle branch block + leave anterior hemiblock Other clinically significant cardiac disease Uncontrolled Db Active uncontrolled infection require intravenous antibiotic Impairment GI function/GI disease may significantly alter absorption Gleevec , hydroxyurea and/or RAD001 Acute/chronic liver/renal disease Other concurrent severe and/or uncontrolled medical condition could cause unacceptable safety risks/compromise compliance w protocol Treatment w hematopoietic colonystimulating factor ≤2wks prior start study drug . Erythropoietin allow Pts w history CHF/arrhythmias receive treatment w digoxin/verapamil , &amp; treatment discontinued/switched different drug prior start study drug Pts take warfarin sodium Pts receive treatment w PDGF/mTOR direct therapy Pts receive chemo ≤ 4wks prior start study drug/have recover side effect therapy Pts receive immunotherapy ≤2 wks prior start study drug/have recover side effect therapy Pts receive investigational drug ≤4 wks prior start study drug/have recover side effect therapy Pts receive XRT ≤4 wks prior start study drug/have recover side effect therapy Pts undergone major nonCNS surgery ≤2 wks prior start study drug/pts recover side effect therapy Cardiac pacemaker , Ferromagnetic metal implant approve safe use MR scanner , Claustrophobia , Obesity Female pt pregnant/breast feeding , /adults reproductive potential employ effective method birth control . Barrier contraceptives must use throughout trial sex . Oral , implantable/injectable contraceptive may affect cytochrome P450 interaction , &amp; therefore consider effective study . Women childbearing potential negative serum pregnancy test 48hrs prior administration Gleevec , hydroxyurea and/or RAD001 . Known diagnosis HIV infection Pts w history another primary malignancy currently clinically significant/currently require active intervention Pts unwilling to/unable comply w protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>RAD0001</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Droxia</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Hydrea</keyword>
	<keyword>Hydroxycarbamide</keyword>
	<keyword>Recurrent GBM</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Glioblastoma multiforme</keyword>
</DOC>